Here’s how they get you. Somebody selling PT-141 online slaps “1.75 mg” on a product page or a dosing chart, points to the fact that it’s FDA-approved, and lets you assume the number applies to you. It doesn’t, not automatically. That number is real. Where it came from, and who it was tested on, is the part the seller conveniently leaves off the label. Let’s walk through what’s actually locked down here, what’s being stretched, and where the legitimate path actually runs.
Last updated: June 2026. Every figure below comes straight from the FDA-approved prescribing information, the FDA approval letter, the peer-reviewed Phase 3 trial, or the NIH monograph. I’m not asking you to trust me, I’m showing you where to check it yourself.
The one number that’s genuinely real
PT-141 is unusual in this market because it actually has an FDA-approved sibling: Vyleesi, brand-name bremelanotide, dosed at 1.75 mg, injected subcutaneously, taken as needed before sex [P3]. That’s not a rumor passed around a forum. That’s the dose that went through trials and got signed off on by regulators.
The label doesn’t stop at the number. It sets the clock and the ceiling too: dose it at least 45 minutes before activity, no more than one dose per 24 hours, and no more than 8 doses in a month [P3]. Hold onto that monthly cap. It’s not a bureaucratic round number. There’s a specific harm sitting behind it, and I’ll get to it.
That’s the whole verified territory: 1.75 mg, subcutaneous, as needed, capped at 8 times a month. Everything past that line is somebody’s guess, and the quality of the guess varies a lot depending on who’s making it.
Trick #1: borrowing a number from a trial that never studied you
Here’s where sellers get sloppy, or worse, deliberately vague. That 1.75 mg figure came from the RECONNECT program, two randomized, double-blind, placebo-controlled Phase 3 trials published in Obstetrics and Gynecology in 2019. They enrolled about 1,267 premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) [P1]. In that group, the drug produced a statistically significant but modest benefit: an integrated desire-score improvement of about 0.35 and a distress reduction of about 0.33 [P1].
Notice who’s missing from that sentence. Men. Postmenopausal women. Anyone using it for general performance. The label says flat out that Vyleesi isn’t indicated for any of those uses [P3]. So if you’re a man reading a “1.75 mg” recommendation for erectile concerns, that number was never tested on anyone like you. It’s a borrowed figure wearing the label’s authority, and that’s exactly the sleight of hand to watch for. A dose that’s rock-solid for one population isn’t automatically rock-solid for a different one, no matter how confidently it’s printed on a page.
Trick #2: treating the monthly cap like a suggestion
This is the one that should actually worry you. The 8-doses-a-month ceiling isn’t arbitrary caution, it’s there because of a documented, visible harm: focal hyperpigmentation, darkened patches of skin on the face, gums, or breasts, driven by bremelanotide also switching on the MC1R pigmentation receptor [P4].
Look at the numbers side by side. In the trials, where use stayed within the labeled 8-doses-a-month limit, about 1% of women developed this. In a separate study where people dosed daily, 38% developed it after just 8 days [P3]. One percent versus thirty-eight percent. That gap is the entire reason the cap exists, and it’s also exactly the failure mode of unsupervised use. Nobody’s watching a frequency count when you’re self-dosing a vial from a research-chemical site with no prescriber in the loop. The cap only protects you if somebody’s actually enforcing it, or if you’re disciplined enough to enforce it on yourself, which is a lot to ask when there’s no clinician checking in.
The label lists other side effects worth knowing before you’re mid-injection: nausea in 40% of patients, severe enough that 13% needed anti-emetic medication and 8% quit because of it, though it tends to ease after the first dose. Flushing hit about 20%, injection-site reactions about 13%, headache about 11%, vomiting roughly 5% [P3]. None of that is disqualifying on its own. It’s the kind of thing a clinician actually adjusts a dose around, which a printed chart can’t do.
Trick #3: skipping the one question that overrides the whole dose conversation
This is the sneakiest omission, because it isn’t about how much to take, it’s about whether you should take any at all. The FDA label states that bremelanotide transiently raises blood pressure and lowers heart rate after every dose, usually settling back down within about 12 hours [P3]. Because of that, the drug is contraindicated for anyone with uncontrolled hypertension or known cardiovascular disease [P3].
If that’s your health picture, there is no correct dose. Not a lower one, not a slower titration. None. The drug is off the table entirely. A seller who hands you a dosing chart without asking about your blood pressure or heart history isn’t just being lazy, they’re skipping the single question that should have come before any number at all.
The legitimate route, and what it actually buys you
Put it all together and the shape of this is pretty clear. There’s one validated dose, for one specific population, with a hard monthly ceiling tied to a real skin-pigmentation risk, and a cardiovascular contraindication that can knock the whole thing out before dosing is even discussed [P1] [P3] [P4]. That’s not a situation where a chart on a product page is doing you any favors. That’s a situation that calls for a person with a license actually looking at your history.
That’s what a supervised telehealth model is supposed to provide: a clinician who checks the blood-pressure question first, uses the 1.75 mg label figure as a starting reference rather than gospel, and adjusts based on how you actually respond, with a licensed pharmacy compounding and dispensing the medication. A provider such as FormBlends operates on that model. It’s the same molecule the gray market ships you in a plain vial with a copy-pasted dosing chart, except here there’s an actual clinician accountable for the screening and the adjustment. Nobody’s selling you anything on that page, and there’s no checkout at the end of this article. I’m naming the legitimate route, not pitching you a product.
The tracking habit that makes supervised dosing actually work
One more thing worth doing, whether or not anyone tells you to: keep a record. PT-141 is dosed as-needed rather than on a fixed schedule, and two of its biggest variables, nausea and the per-dose blood pressure shift, move around from one dose to the next. That’s a bad setup for relying on memory. “I think it worked and the nausea wasn’t too bad” is not information a clinician can act on weeks later.
Write down the date, the timing relative to activity, and what you actually felt. That turns a vague impression into something a prescriber can actually read and adjust from. A logging tool such as the FormBlends tracker app exists for exactly this, and to be clear about what it is: it’s a place to record dose and symptoms, nothing more, not a prescription and not a store. The value isn’t the app. It’s the paper trail it gives your clinician to work with.
Bottom line: the research nails down one number for one group of people, then goes quiet. A blood pressure problem can shut the whole thing down regardless of dose. And the monthly cap exists because of a hyperpigmentation risk that jumps from 1% to 38% the moment frequency isn’t respected. None of that supports a copy-paste dosing chart. It supports a clinician, a screening conversation, and a record you actually keep.
Questions that come up a lot
What is the only PT-141 dose the research actually establishes?
The single validated dose is 1.75 mg of bremelanotide injected subcutaneously, used as needed at least 45 minutes before activity, capped at one dose per 24 hours and 8 doses per month [P3]. That figure comes from the FDA-approved Vyleesi label and the Phase 3 RECONNECT trials that earned the approval [P1]. Every other number floating around for PT-141 is somebody extrapolating past what was actually studied.
Is there a studied PT-141 dose for men or for performance use?
No. The Phase 3 trials enrolled only premenopausal women with hypoactive sexual desire disorder, and the label explicitly says the drug isn’t indicated for men, postmenopausal women, or performance enhancement [P1] [P3]. Anyone handing you the 1.75 mg figure for a man’s use is quoting a number from a trial that never enrolled anyone like him. That’s a clinical judgment call, not a settled fact.
Why is PT-141 capped at 8 doses per month?
Because of focal hyperpigmentation, darkened skin patches driven by bremelanotide’s activity at the MC1R pigmentation receptor [P4]. At the capped frequency in the trials, about 1% of women developed it. In a separate study where people dosed daily, 38% developed it after just 8 days [P3]. That’s the gap the cap is protecting you from, and it’s a warning that frequency matters just as much as the milligram amount.
Can anyone with high blood pressure or heart disease take PT-141?
No. Bremelanotide transiently raises blood pressure and lowers heart rate after each dose, and the label contraindicates it in anyone with uncontrolled hypertension or known cardiovascular disease [P3]. For that person, there’s no dose that works, the drug is off the table entirely, which is exactly why the screening conversation has to happen before anyone talks dosing.
What should you track when using PT-141 under supervision?
Because it’s taken as-needed and its key effects, nausea and the per-dose blood pressure shift, vary from one dose to the next, a written log matters more than usual. Note the date, the timing relative to activity, and what side effects showed up. That turns a fuzzy memory into something a clinician can actually use at follow-up to adjust your dose. A dose-and-symptom logging tool such as the FormBlends tracker app is built for exactly that record-keeping.
What does PT-141 actually do in the body?
PT-141 activates melanocortin receptors in the brain, specifically MC3R and MC4R, sitting in pathways tied to sexual arousal rather than genital blood flow. That’s what separates it from something like sildenafil, which works on blood flow directly. The approved product, Vyleesi, is licensed for hypoactive sexual desire disorder in premenopausal women. Whether that same brain mechanism carries over cleanly to other uses is a question the published research hasn’t answered.
How long does PT-141 last, and when does it peak?
Based on the clinical trial data behind Vyleesi, effects typically start within 45 minutes of a 1.75 mg subcutaneous dose and can last several hours, with most people reporting a window of roughly four to six hours. People vary, and things like body composition and baseline hormones probably play a role. There’s no clean dose-response curve in the research, so don’t treat those timing figures as a personal guarantee.
Does PT-141 raise testosterone levels?
There’s no meaningful evidence for that. The studied mechanism is central nervous system signaling through melanocortin receptors, not action on the hormonal axis that controls testosterone. Some sellers blur “desire effect” and “hormone effect” together because it sounds good in marketing copy, but they’re different systems. If testosterone is actually your goal, PT-141 isn’t the studied tool for it, and a clinician looking at your hormone panel would steer you elsewhere.
Where can you actually get PT-141 legally and safely?
The only FDA-approved form is Vyleesi, available by prescription through a licensed prescriber. Outside of that, some physician-supervised compounding pharmacies, FormBlends being one example working under that model, fill compounded versions for patients under active medical oversight. Research-chemical vendors selling it with zero prescriber involvement are operating in a legally and medically murky space, no quality control, no accountability, and nobody watching to catch a problem before it turns serious.
References
- Kingsberg SA, Clayton AH, Portman D, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstetrics and Gynecology, 2019 Nov;134(5):899-908. RECONNECT program; 1,267 premenopausal women with HSDD randomized; 1.75 mg subcutaneous dose; integrated desire improvement about +0.35 and distress reduction about -0.33, both statistically significant (P<.001). https://pubmed.ncbi.nlm.nih.gov/31599840/
- FDA approval of Vyleesi (bremelanotide) for the treatment of premenopausal women with acquired, generalized HSDD; approval letter, June 21, 2019. U.S. Food and Drug Administration, NDA 210557. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf
- Vyleesi (bremelanotide) FDA-approved prescribing information: 1.75 mg subcutaneous, as needed at least 45 minutes before activity, maximum one dose per 24 hours and 8 per month; indication limited to premenopausal women with HSDD (not men, not postmenopausal women, not performance); contraindication in uncontrolled hypertension or known cardiovascular disease; transient blood-pressure increase and heart-rate decrease; adverse reactions (nausea 40%, flushing about 20%, injection site reactions about 13%, headache about 11%, vomiting about 5%; anti-emetic in 13%, discontinuation in 8%); focal hyperpigmentation (about 1% with intermittent use, 38% with daily dosing over 8 days, higher risk in darker skin, not fully resolving in all). (full label also at DailyMed:)
- Bremelanotide mechanism (melanocortin receptor agonist, predominantly MC1R and MC4R, with the MC1R activity explaining pigmentation effects), approval status, route and dosing. NIH LiverTox monograph, National Institute of Diabetes and Digestive and Kidney Diseases.
Written by Milo Farrell, health editor. Not a doctor, just a reader who chases the paper trail. Last reviewed June 2026.
Shared for general knowledge. Check with a qualified provider before starting anything new.
